Applied DNA Sciences Files 8-K on Security Holder Votes

Ticker: BNBX · Form: 8-K · Filed: Sep 30, 2024 · CIK: 744452

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: APDN

TL;DR

APDN filed an 8-K for shareholder votes on 9/30 - details to follow.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on September 30, 2024, to report on matters submitted to a vote of its security holders. The filing does not detail the specific proposals voted on or the outcomes, but it serves as an official record of these corporate governance events.

Why It Matters

This filing is important for investors to understand the outcomes of shareholder votes, which can impact corporate strategy, leadership, and shareholder rights.

Risk Assessment

Risk Level: low — This filing is procedural and reports on a vote, without immediate financial or operational impact disclosed.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders by Applied DNA Sciences, Inc. on September 30, 2024?

The filing states that matters were submitted to a vote of security holders, but the specific proposals are not detailed in the provided excerpt.

What is the primary purpose of this 8-K filing for Applied DNA Sciences, Inc.?

The primary purpose is to report on the submission of matters to a vote of security holders, as required by SEC regulations.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on September 30, 2024.

What is the Commission File Number for Applied DNA Sciences, Inc.?

The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.

Where is Applied DNA Sciences, Inc. headquartered?

Applied DNA Sciences, Inc. is headquartered at 50 Health Sciences Drive, Stony Brook, New York 11790.

Filing Stats: 648 words · 3 min read · ~2 pages · Grade level 10.8 · Accepted 2024-09-30 16:50:40

Key Financial Figures

Filing Documents

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On September 30, 2024, Applied DNA Sciences, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). The following proposals were voted on and were approved by the Company's stockholders at the Annual Meeting with the stockholders having voted as set forth below: I. To elect six directors to serve until the 2025 annual meeting of stockholders or until their respective successors are duly elected and qualified. FOR WITHHELD BROKER NON- VOTES James A. Hayward 2,364,477 905,861 1,942,975 Robert B. Catell 2,384,561 885,777 1,942,975 Joseph D. Ceccoli 2,384,568 885,770 1,942,975 Yacov A. Shamash 2,382,506 887,832 1,942,975 Sanford R. Simon 2,383,486 886,852 1,942,975 Elizabeth Schmalz Shaheen 2,380,507 889,831 1,942,975 II. To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending September 30, 2024. FOR AGAINST ABSTAIN 4,411,771 649,039 152,503 III. To grant the board of directors of the Company (the "Board") discretionary authority for 12 months to amend the Company's certificate of incorporation, as amended, to authorize a reverse stock split of common stock, at a ratio in the range from one-for-five to one-for-fifty, with such specific ratio to be determined by the Company's Board following the Annual Meeting. FOR AGAINST ABSTAIN 3,700,381 1,229,326 283,606 IV. To approve, in accordance with Nasdaq Listing Rule 5635(d), the exercisability of certain common stock purchase warrants, and the issuance of the common stock underlying such warrants, which warrants were issued in connection with an offering of securities of the Company that occurred on May 28, 2024. FOR AGAINST ABSTAIN BROKER NON-VOTES 2,222,880 989,536 57,922 1,942,975 Each of the foregoing voting results from the Annual Meeting is final. Based on the foregoin

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing